92 results about "Plasma samples" patented technology

The utility model discloses a full-automatic whole blood sample pretreatment device for separating plasma through immunomagnetic beads. The full-automatic whole blood sample pretreatment device comprises a plasma separation mechanism for extracting a plasma sample from a whole blood sample, a conveying mechanism for conveying a blood collection tube and a sample cup, and a feeding mechanism for providing the sample cup, the plasma separation mechanism comprises a sample loading and shaking module for uniformly mixing a whole blood sample in the blood collection tube, a puncture sampling module for collecting the whole blood sample or the plasma sample, and a magnetic separation module for separating the plasma sample; the magnetic separation module comprises an oscillation assembly, a magnetic attraction assembly and a reaction cup, and freeze-dried immunomagnetic beads and an antibody reagent are pre-stored in the reaction cup. The device provided by the utility model can be used for comprehensively and automatically pretreating a whole blood sample and improving the quality and the efficiency of plasma separation.

The invention relates to the technical field of molecular biology, in particular to application of a gene marker in early screening of multiple alimentary canal cancer species, an early screening model construction method and a detection device.WGS low-depth sequencing is conducted on plasma sample cfDNA, and three difference characteristics including copy number change, copy number change, cfDNA fragment change, cfDNA fragment change, cfDNA fragment change, cfDNA fragment change, cfDNA fragment change, cfDNA fragment change, cfDNA fragment change, cfDNA fragment change, cfDNA fragment change, cfDNA fragment change and cfDNA fragment change are analyzed according to a high-throughput sequencing result. The method comprises the following steps of: performing training modeling by using a convolutional neural network according to a DNA fragment size ratio and a nucleosome covering mode, realizing high-specificity and high-sensitivity accurate early detection on a plurality of cancers under low sequencing depth, and performing training modeling by using five algorithms, namely a generalized linear model, gradient boosting, a random forest, deep learning and extreme gradient boosting respectively, so as to realize accurate early detection on the plurality of cancers under low sequencing depth. The generalized linear model is subjected to secondary set training to construct multi-feature algorithm integration, and the purpose of tissue traceability detection of multiple cancer species is achieved.

A plasma digital marker mining and disease classification device comprises a plasma sample spectrum acquisition module used for determining a digital marker sorting cluster in a plurality of plasma samples; the plasma candidate digital marker selection module is used for iterating plasma spectrum samples in the initial disease classification device based on the digital marker sorting cluster to obtain a plasma candidate digital marker cluster; the pathogenic protein digital marker cluster acquisition module is used for acquiring pathogenic protein digital marker clusters corresponding to spectral absorption peaks of various related pathogenic proteins; the plasma digital marker mining module is used for determining an intersection of the plasma candidate digital marker cluster and the pathogenic protein digital marker cluster as a plasma digital marker; and the disease classification device construction module is used for training a disease classification device according to the plasma digital markers to obtain a trained disease classification device. By adopting the technical scheme, a disease classification device capable of accurately distinguishing MCI patients can be constructed.

The invention relates to the technical field of plasma concentration monitoring methods, in particular to a method for rapidly detecting the content of tacrolimus in plasma through paper spray mass spectrometry. The method provided by the invention comprises the following steps: adding a to-be-detected plasma sample into a precipitation solution, vortex, taking supernate, and dropwise adding the supernate onto a paper base; spraying voltage is applied to the paper base, the paper base generates electrospray, and the electrospray enters a mass spectrometer for detection; preparing a gradient matrix matched tacrolimus standard solution, replacing the to-be-detected plasma sample with the gradient matrix matched tacrolimus standard solution, repeating the operation, recording a detection result, and drawing a standard curve by taking the matrix matched tacrolimus concentration as an abscissa and taking peak area data acquired by a mass spectrometer as an ordinate; and comparing the recorded detection result with the drawn standard curve, and quantitatively analyzing the content of tacrolimus in the to-be-detected plasma sample. The method disclosed by the invention is simple to operate and high in analysis speed, has relatively good precision and accuracy and also has high sensitivity and high selectivity.

The invention relates to the technical field of biology, and discloses a fetus genotype detection method based on haplotype. The method comprises the following steps: 1) performing cfDNA sequencing on a to-be-tested pregnant woman plasma sample with known haplotype parting of a mother and a father to obtain a sequencing read section; 2) comparing the sequencing read segment to a reference genome, and estimating depth distribution and mutation of the sample according to a comparison result; 3) for four types of allele sites, the concentration of the fetal sample is calculated according to the secondary allele frequency, and the four types of allele sites comprise mother homozygous fetal homozygous, mother homozygous fetal heterozygous, mother heterozygous fetal homozygous and mother heterozygous fetal heterozygous; and 4) for genotype combinations AAAB, ABAA and ABAB of the mother and the father, deducing fetal SNP and InDel genotypes. The method disclosed by the invention can be used for detecting the single-point variation in the whole genome range, so that the accuracy is improved, and the sequencing depth is effectively reduced.

The current application reveals a method, apparatus, device, and storage medium for detecting micro residual lesions, falling within the domain of medical detection technology. This method is based on differentiated deep whole-exome / targeted drug sequencing and tissue-blood cell-plasma co-capture technology, and 100,000× ultra-high depth personalized / high evidence hotspot combination panel sequencing to evaluate tiny residual lesions and tumor evolution / second primary in plasma samples. It resolves the challenges of existing techniques, such as elevated tissue detection thresholds, restricted tracking locations, inadequate detection sensitivity and precision, or elevated costs when ctDNA concentrations in the bloodstream are minimal. Furthermore, it surmounts the challenge of simultaneously achieving personalized tracking detection and monitoring tumor evolution or second / primary detection. It markedly boosts the precision of forecasting the likelihood of recurrence following patient therapy within a restricted budget.

The invention provides a non-invasive fetal trisomy 21 syndrome prenatal screening kit based on digital PCR, and relates to the technical field of fetal trisomy 21 syndrome screening, according to a method for enriching fetal cfDNA in pregnant woman plasma, SPRIselect magnetic beads with low enrichment multiple and silicon hydroxyl magnetic beads are combined for use, and under a certain dosage, the recovery rate of fetal cfDNA short fragments reaches 95%; according to the provided multiple system construction method, positive gDNA and negative gDNA are obtained on the basis of a 21 trisomy positive cell line and a 21 trisomy negative cell line, low-proportion reference substances are prepared and used, internal reference sites and detection sites which are high in detection capacity and stable in detection performance are screened from the beginning, and compared with existing multiple system establishment and verification through direct use of pregnant woman plasma samples, the multiple system construction method has the advantages that the detection efficiency is high, and the detection cost is low. The to-be-detected sample with lower fetal cfDNA content can be stably detected.

The invention discloses a disease risk assessment method and screening device based on a multi-group student physical collaborative digital network, and relates to the field of intelligent medical detection. In order to solve the defect that multi-omics-level system collaborative analysis and robust risk assessment are difficult to realize in the prior art, the technical scheme provided by the invention is as follows: acquiring a plasma sample, acquiring a spectral signal by adopting an attenuated total reflection Fourier transform infrared spectrum, and establishing a plasma spectrum digital information space; the method comprises the following steps: constructing a biological collaborative digital network containing four nodes of protein, lipid, saccharides and nucleic acid based on pathophysiology priori knowledge, and defining node strength, edge weight and network collaborative efficiency; a health baseline configuration file is established by using a health sample, a standardized deviation score of a to-be-tested sample is calculated, a comprehensive risk score is obtained, a disease screening result is output in combination with a machine learning model, and digital evaluation of multi-omics collaborative characteristics is realized. The method is suitable for non-invasive rapid screening and risk assessment work of neurodegenerative diseases and mental diseases.

The invention relates to the technical field of nucleic acid detection, and discloses an integrated nucleic acid detection device compatible with multiple sample types and a nucleic acid detection method.The nucleic acid detection device comprises multiple cavities, and a saliva sample bin, a plasma sample bin and a nasopharynx swab sample bin are arranged at the top end of a nucleic acid extraction cavity; the test strip detection chamber comprises a first test paper chamber and a second test paper chamber, and the second test paper chamber is in sliding connection with the first test paper chamber; a through hole penetrating through the two end faces of each cavity is formed in each cavity, thorn-shaped structures extending towards the top faces of the cavities are arranged on the side walls of the through holes, the bottom ends of the through holes are sealed through sealing films, and the thorn-shaped structures are used for puncturing the corresponding sealing films; the test paper is fixed in the test paper storage groove of the second test paper chamber, the test paper storage groove is communicated with the through hole in the first test paper chamber, and the test paper strip detection chamber is provided with a detection result output window for outputting a detection result. Detection is easy to operate, the detection process is in a sealed state, environmental pollution is avoided, and various samples can be compatible.

To provide a method for determining a stability status of microsatellite loci using a plasma sample from a cancer patient based on next-generation high-throughput sequencing.SOLUTION: A method comprises the following steps: 1) determining length characteristics of repetitive sequences of multiple microsatellite loci in a plasma sample and a MSS plasma sample as a reference sample on the basis of next-generation sequencing method; 2) calculating its corresponding enrichment index Z score for any one of microsatellite loci; 3) summing the enrichment index Z score of all microsatellite loci to calculate the index MS score for determining the status of microsatellites of the sample; 4) calculating a mean and a standard deviation SD of the MS score of the MSS plasma sample as the reference sample, with mean+3SD as the threshold cutoff; and 5) performing determination using the MS score and cutoff.SELECTED DRAWING: None

The invention relates to a biomarker-based near infrared spectrum characteristic wave band screening and pan cancer grading detection system and a working method thereof, and the working method comprises the following steps: a spectrum collection unit collects the near infrared spectrum of a to-be-detected plasma sample to obtain spectrum data; a spectrum abnormal value eliminating unit eliminates abnormal values; the clinical biochemical data abnormal value eliminating unit is used for eliminating abnormal values of the biochemical detection data; selecting a sample set division method and a division proportion; the spectrum pretreatment unit is used for pretreating a near infrared spectrum of a to-be-detected plasma sample; the spectral characteristic wave band screening unit screens spectral characteristic wave bands in combination with clinical biochemical indexes and near infrared spectrums, so that the accuracy of pan cancer recognition is improved; and the data analysis unit performs qualitative discriminant analysis on the near infrared spectrum data, constructs an accurate cancer primary detection model and an accurate cancer accurate detection model, preliminarily identifies cancers and finely screens esophageal squamous cell carcinoma, gastric cancer, colorectal cancer and lung cancer samples. The method has good practical application and reference value for large-scale screening of cancers.

The present invention relates to a ctDNA-based solid tumor MRD detection method, detection system, and computer-readable medium, and belongs to the technical field of tumor gene detection. The present invention proposes a method for qualitatively characterizing plasma sample MRD based on tissue baseline mutation sites during dynamic plasma testing. This method calculates the background error rate of single-base mutations, simulates mutation readings based on this error rate, and compares them with the actual observed mutation readings. The number of times the simulated mutation readings are greater than the actual observed mutation readings is statistically analyzed. The p-value of the sample ctDNA positive is calculated based on multiple simulation results at the mutation site.

The invention belongs to the technical field of chemical screening, and particularly relates to a systematic screening method for rubber-related chemicals in a plasma sample, which comprises the following steps: S1, taking the plasma sample, adding a mixed extraction solvent, extracting, centrifugally layering, collecting supernate, repeatedly extracting, merging the supernate, concentrating, and freezing to obtain a rubber-related chemical sample; centrifuging again, adding an isotope internal standard, and carrying out data dependence acquisition in a positive and negative ion analysis mode by adopting liquid chromatography-tandem high-resolution mass spectrometry. According to the invention, the comprehensive coverage type monitoring of 1300-1500 RDCs in the plasma sample is realized. By means of combination of a positive and negative ion double analysis mode and data dependence acquisition, the detection range and the signal response stability of the RDCs with different polarities are effectively considered, and the technical problem that in the prior art, the composite effect generated by coexistence of multiple RDCs is ignored is solved.

The invention discloses a preparation method of a blood coagulation factor quality control product. The preparation method comprises the following steps: treating mixed plasma of multiple persons by using a physical and chemical method; and mixing the multi-person mixed plasma with the factor diluent according to a certain proportion to prepare the blood coagulation routine item quality control product with different blood coagulation routine item contents at different concentration levels, subpackaging, and storing in an ultra-low temperature refrigerator at-80 DEG C to obtain the blood coagulation routine item quality control product. The blood coagulation routine item quality control product prepared by the invention is good in product uniformity, stability and frozen product remelting stability, can replace commercial products to be used for quality control of blood coagulation routine item detection, and is beneficial to reducing the detection cost and improving the blood coagulation routine item detection capability.

To provide an assay kit that improves stability of a reagent containing NAD(P)H and enhances shelf life, in an enzyme-based test for ammonia that can be used for analysis of plasma samples taken from patients in clinical settings.SOLUTION: In an exemplary reagent, ammonia released as a result of NAD(P)H decay is scavenged using an enzymatic reaction to convert the ammonia using GLDH, NAD(P)H and 2-oxoglutarate, thereby forming L-glutamate, NAD(P)+ and H2O in the NAD(P)H containing reagent.SELECTED DRAWING: None

The present application relates to the field of bioinformatics, and specifically provides a lung cancer early screening model construction and application based on FDEM / FDBM feature extraction from LP-WGS sequencing data and PCC system noise reduction. By performing low-depth whole-genome sequencing of plasma sample cfDNA, high-throughput sequencing of lung cancer and healthy human cfDNA, extracting new features from the sequencing results, and using the PCC (Principal Component Correction) method to reduce background noise of the new features to improve the signal-to-noise ratio of cancer signals, a highly sensitive machine learning model for distinguishing lung cancer from healthy people is constructed, and ultimately achieving high-precision identification of lung cancer patients.

The application discloses a combined filter for separating plasma from whole blood, comprising a whole blood sample adding chamber, a first combined filter membrane, an intermediate chamber, a second combined filter membrane and a plasma collecting chamber arranged in sequence along a filtering direction of a whole blood sample flow; and the whole blood sample is filtered multiple times through the first combined filter membrane and the second combined filter membrane to obtain a plasma sample. The application further provides a combined filter device and a method for separating plasma from whole blood. The combined filter provided by the application can further improve the recovery rate, recovery quality and recovery efficiency of the whole blood separation plasma, and meets the demand of in-vitro diagnosis on the pretreatment of the whole blood sample.

This invention relates to the field of medical technology, specifically to a method for preoperative risk assessment and prediction in liver transplant patients with hepatocellular carcinoma, comprising the following steps: Sample collection: selecting plasma samples and corresponding clinicopathological information from liver transplant recipients of hepatocellular carcinoma, and clarifying the inclusion and exclusion criteria for samples; Plasma cell-free DNA extraction and whole-genome sequencing: extracting and quality-controlling cell-free DNA from the plasma samples collected in step S1, constructing a sequencing library, and performing low-coverage whole-genome sequencing. This invention utilizes plasma-extracted cfDNA for whole-genome sequencing, combined with clinical testing information, to construct a preoperative risk assessment and prediction model for postoperative recurrence in liver transplant recipients of hepatocellular carcinoma based on non-invasive testing. This model can be used to predict the probability of recurrence-free survival before liver transplantation. The model derivation cohort integrates clinical records and circulating tumor DNA data for preoperative recurrence risk prediction.

Plasma sampling interface (20) for an inductively coupled plasma mass spectrometer (ICP-MS), wherein the plasma sampling interface comprises • a housing (26) comprising an inlet opening (31) for introducing ions from plasma (24) generated by an inductively coupled plasma source (10) into an inner chamber (27) of the housing (26) and an outlet opening (25) for releasing ions from the inner chamber (27); • a sampler (70) with a sampling opening (71), wherein the sampler (70) is mounted on the housing (26), wherein the sampler (70) is arranged in use adjacent to the plasma (24) generated by the inductively coupled plasma source (10) in order to extract ions from the plasma (24) and to release ions extracted as a sample through the inlet opening (31) into the inner chamber (27), wherein the inlet opening (31) is provided in a cooling plate (30) which is integral with the housing (26), wherein the sampler (70) is mounted on the cooling plate (30) in order to at least partially cover the inlet opening (31), characterized in that the cooling plate (30) is made of bronze.

The utility model belongs to the technical field of blood samples, and particularly relates to a plasma sample preservation device which comprises a box body and a hinged box cover, a placing table and a partition plate are fixedly connected to the upper portion and the lower portion of the interior of the box body respectively, openings distributed in a matrix mode are formed in the surface of the placing table, and preservation assemblies are installed above and below the openings. The storage assembly comprises a storage pipe and a threaded ring; when the test tube is placed or taken out, the sealing cap is opened, the sealing cover abuts against the bottom end of the storage tube for sealing to reduce heat transfer, and after the test tube is placed or taken out, the sealing cap is connected with the threaded ring to seal the top end of the storage tube and open the bottom end of the storage tube, so that cold air enters the storage tube to refrigerate the test tube. Compared with the prior art, when the test tube is placed or taken out, the loss amount of cold air is reduced, and heat transfer can be greatly reduced.

The invention provides methods for simultaneously enriching multiple target regions of interest in one reaction volume, from cell-free DNA isolated from a blood or plasma sample, followed by high-thought sequencing and sequence read analysis. The invention also provides library of target-specific oligonucleotide primers or probes for the multiplexed target enrichment.

The invention relates to a primer probe set for HBV (hepatitis B virus) in-vitro diagnosis, which comprises an internal standard primer probe set and a target primer probe set which are amplified in the same environment, and the internal standard primer probe set and the target primer probe set are configured as follows: the difference between the target probe and the internal standard probe is not more than 5 DEG C according to the fusion degree; the melting temperature of the probe of the internal standard is 5-10 DEG C higher than the melting temperature of the upstream and downstream primers of the internal standard; the probe melting temperature of the target is set to be 5-10 DEG C higher than the melting temperature of upstream and downstream primers of the target. According to the technical scheme, through three-dimensional technology coupling of melting temperature cooperative control, amplification kinetics synchronous optimization and sequence structure differentiation design, a comparison test of homologous serum and a plasma sample is completed aiming at the plasma sample in clinical verification, the positive coincidence rate, the negative coincidence rate and the total coincidence rate are 99.49%, 86.67% and 98.57% respectively, and the positive coincidence rate, the negative coincidence rate and the total coincidence rate are both 99.49%, 86.67% and 98.57% respectively. The internal standard designed by the technology can be further expanded to the field of detection of various RNA / DNA viruses including HIV-1, and a standardized solution is provided for development of molecular diagnosis kits.

A biological sample processing device including a blood filtration module and an extraction module incorporated within a common housing. The blood filtration module has a dual filter structure. The extraction module includes a series of chambers that hold agents to effect any one or more of lysis, binding of target material to capture beads, washing, elution, and / or nucleic acid amplification. Moveable magnets are used to move the beads through the chambers to perform the extraction process. A second magnet-based device for preparing largely pure plasma samples from whole blood in the field.

Systems and methods for quantifying circulating tumour DNA (ctDNA) in a plasma sample by performing fragment length analysis of the sequencing data using a ctDNA quantification model to estimate a ctDNA metric of the blood plasma sample. Wherein the ctDNA quantification model comprises a neural network based system trained using a training dataset generated using control cfDNA data augmented with ctDNA data obtained from known cancer samples to generate artificial training dataset records with a known ctDNA metric.

The present invention discloses a method for constructing a dual-omics plasma fingerprint model and an infection diagnosis device of the dual-omics plasma fingerprint model constructed by using this method, which relates to the technical field of infection disease diagnosis. The construction method includes preprocessing plasma samples, preparing matrix materials, spotting samples and matrixes on a mass spectrometry target plate, collecting plasma metabolite fingerprints in nanoparticle-enhanced laser desorption ionization mass spectrometry, and collecting plasma protein fingerprints in organic matrix material-assisted laser desorption ionization mass spectrometry. The infection diagnosis device performs data analysis on the dual-omics plasma fingerprint map to obtain a diagnosis result, and has advantages such as high detection reproducibility, fast analysis speed, and less sample consumption, realizing high-efficiency diagnostic performance for different infection types.

The present invention provides a method of determining endometrial status using a sample (e.g., a plasma sample) from a subject, comprising: (a) performing an assay on a blood sample from a subject to determine a miRNA expression profile wherein the miRNA expression profile comprises a plurality of expression levels of miRNAs, and (b) analyzing the miRNA expression profile using a computer-based machine learning model to obtain a predicted score.

The present invention discloses a one-time injection high-efficiency microfluidic detection chip, the detection chip has a rotation center, and the detection chip includes at least one detection unit that can independently perform detection, the detection unit includes a mixed cultivation tank for providing a reaction space, and a solid reagent storage tank storing N different solid reagents is arranged in the mixed cultivation tank; the solid reagent includes a first, a second, ..., and an Nth solid reagent, all of which are coated with a protective film on the outside, and the outside of the Nth solid reagent is sequentially coated with a first protective film, a second protective film, ..., and an Nth protective film from the outside to the inside. The present invention can directly use whole blood, peripheral blood, serum, and plasma samples without sample pretreatment; it can process samples of high hematocrit / polycythemia; only one-time injection of the sample is required to automatically complete complex sample addition and reaction steps; it can reduce the overall reaction time without affecting the detection efficiency, and quickly complete blood testing.

The present invention relates to a method for determining whether an unknown blood sample is a serum sample, a citrated plasma sample, or an EDTA-treated plasma sample. The invention also relates to a method for the diagnosis and / or monitoring of a patient suffering from a hemostasis disorder.

The present disclosure deals with the biochemistry of reagents useful in the detection of ammonia in liquid samples. Specifically, the present disclosure is directed to a technical improvement of an enzyme-based test for ammonia that can be used for analysis of plasma samples taken from patients in clinical settings, among other uses. In this regard, stability of a reagent containing NAD(P)H is improved, enhancing shelf life and results in the detection of ammonia. In an exemplary reagent ammonia released as a result of NAD(P)H decay is scavenged using an enzymatic reaction to convert the ammonia using GLDH, NAD(P)H and 2-oxoglutarate, thereby forming L-glutamate, NAD(P)+ and H2O in the NAD(P)H containing reagent.

The invention discloses a detection system and method, and the system comprises a blood sample collection module which is used for collecting a plasma sample, carrying out the surface enhanced Raman scattering of the plasma sample, and obtaining a plasma component Raman spectrum signal; the Raman signal collection module is used for collecting the Raman spectrum signal, optimizing the Raman spectrum signal, converting the Raman spectrum signal into an electric signal, generating a plasma component frequency shift image according to the converted electric signal, and sending the plasma component frequency shift image to the analysis and diagnosis module; the analysis and diagnosis module is used for comparing the frequency shift image with a tumor marker image in a Raman frequency shift database so as to identify a tumor marker; and tumor characteristics are diagnosed according to the identified tumor markers. The detection system provided by the invention can efficiently and accurately obtain a cerebrospinal fluid detection result.